Breadth and depth of leadership and commercial manufacturing experience a strong fit for company’s growth and culture
Seattle, Washington, USA – December 3, 2014 – CMC Biologics, a leading contract manufacturing organization dedicated to technical excellence in process development and cGMP manufacture of therapeutic proteins, today announced that Joseph Wypych has joined the Company as General Manager of its Seattle facility. Mr. Wypych will manage site operations of CMC Biologics’ clinical and commercial manufacturing facility.
“Joseph brings significant manufacturing and business experience in operations and materials management of clinical and commercial biopharmaceuticals,” said Gustavo Mahler, Chief Operations Officer of CMC Biologics. “His results-oriented approach and focus on people will play a pivotal role in growing our business and strengthening our company culture.”
“It’s a very exciting time to be at CMC Biologics. We are experiencing unprecedented growth globally and are on track to add more than 60 new employees in the next year to meet customer demand for clinical and commercial product needs,” said Wypych. “I am pleased to be a part of this dedicated team and look forward to driving CMC Biologics’ growth and innovation to serve the biologics market.”
Joseph Wypych brings more than 20 years of biopharmaceutical industry expertise in process development and manufacturing. Prior to CMC Biologics, he served as Plant Manager at Baxter Bioscience, Hayward, California. Previously, he held manufacturing and supply chain project management positions at ImClone Systems and Cell Genesys Inc., respectively. Joseph holds a Master of Business Administration from California State University, Hayward and a Bachelor of Science in Biochemistry from the University of California, Davis.
About CMC Biologics CMC Biologics is leading the industry among CMOs in reliability, technical excellence, and quality – Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical and clinical trials, and commercial production. The Company’s wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics’ proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. More detailed information can be found at www.cmcbiologics.com.
Stacie D. Byars CMC Biologics Global Marketing firstname.lastname@example.org +1 (206) 660-2588